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ABSTRACT (248 words) 31 
Aims: Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced 32 
risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme 33 
activity is causally relevant to coronary heart disease (CHD).  34 
Methods: In 72,657 patients with CHD and 110,218 controls in 23 epidemiological studies, we genotyped five 35 
functional variants, four rare loss-of-function mutations (c.109+2T>C[rs142974898], Arg82His[rs144983904], 36 
Val279Phe[rs76863441], Gln287Ter[rs140020965]) and one common modest-impact variant 37 
(Val379Ala[rs1051931]) in PLA2G7, the gene encoding Lp-PLA2.. We supplemented de-novo genotyping with 38 
information on a further 45,823 CHD patients and 88,680 controls in publicly available databases and other 39 
previous studies. We conducted a systematic review of randomized trials to compare effects of darapladib 40 
treatment on soluble Lp-PLA2 activity, conventional cardiovascular risk factors, and CHD risk with 41 
corresponding effects of Lp-PLA2-lowering alleles.  42 
Results: Lp-PLA2 activity was decreased by 64% (p=2.4×10-25) with carriage of any of the four loss-of-function 43 
variants, by 45% (p<10-300) for every allele inherited at Val279Phe, and by 2.7% (p=1.9×10-12) for every allele 44 
inherited at Val379Ala. Darapladib 160mg once-daily reduced Lp-PLA2 activity by 65% (p<10-300). Causal risk 45 
ratios for CHD per 65% lower Lp-PLA2 activity were: 0.95 (0.88-1.03) with Val279Phe; 0.92 (0.74-1.16) with 46 
carriage of any loss-of-function variant; 1.01 (0.68-1.51) with Val379Ala; and 0.95 (0.89-1.02) with darapladib 47 
treatment. 48 
Conclusions: None of a series of Lp-PLA2–lowering alleles was related to CHD risk, suggesting that Lp-PLA2 49 
is not a valid therapeutic target.  50 
 51 
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CHD = Coronary Heart Disease 60 
CI = Confidence Interval 61 
HDL = High-density lipoprotein 62 
LDL = Low-density lipoprotein 63 
Lp-PLA2 = Lipoprotein-associated phospholipase A2 64 
MI = Myocardial infarction 65 
SD = Standard deviation 66 
 67 
Word count: 3003 (excluding references and abstract (248 words)) 68 
3 main figures, 2 tables, 1 Appendix 69 
Supplement (comprising a supplementary note and 6 tables, 4 figures)  70 
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INTRODUCTION 71 
Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme expressed by inflammatory cells in 72 
atherosclerotic plaques, is carried in the circulation bound predominantly to low-density-lipoprotein (LDL)1. Lp-73 
PLA2 (also called platelet-activating factor acetyl hydrolase) hydrolyzes oxidized phospholipids to yield pro-74 
inflammatory products implicated in endothelial dysfunction, plaque inflammation, and formation of necrotic 75 
core in plaque1. Observational2 and experimental studies in humans and animals have suggested that Lp-PLA2 76 
could be a valid therapeutic target, postulating this enzyme to link oxidative modification of LDL and 77 
development of inflammatory responses to arterial intima1. Previous studies have investigated genetic variants 78 
altering Lp-PLA2 function in relation to coronary heart disease (CHD) risk3, 4. However, these studies have 79 
generally yielded inconclusive, or conflicting results3, 4, perhaps due to limited statistical power and to limited 80 
knowledge about variants altering Lp-PLA2 function (i.e., previous studies have been able to consider only one 81 
loss-of-function variant in PLA2G7, the gene encoding Lp-PLA2). 82 
However, two phase 3 randomized trials of darapladib, a potent inhibitor of Lp-PLA2 activity, have not shown 83 
reductions in cardiovascular risk5, 6. These results could, at least in part, have been due to features of the trials. 84 
One of the phase 3 trials was restricted to patients recently hospitalized with acute coronary syndromes5, yet 85 
many cardiovascular events occurring early after acute coronary syndromes may relate to thrombotic 86 
mechanisms and not be modifiable through Lp-PLA2 inhibition. Trials used statins as background therapy, so 87 
any Lp-PLA2 inhibition achieved with statins could have reduced any incremental benefits of darapladib. Trials 88 
could not assess the effects of prolonged Lp-PLA2 inhibition because they recorded only about 3-4 years of 89 
median follow-up5, 6. 90 
An alternative explanation is that darapladib did not reduce cardiovascular risk because Lp-PLA2 is not a causal 91 
risk factor in cardiovascular disease. We tested this possibility by investigating natural loss of Lp-PLA2 activity. 92 
Studies of Lp-PLA2–lowering alleles should complement randomized trials of darapladib because genotypes are 93 
fixed at conception, avoiding potential distorting effects of pre-existing disease and medication usage. 94 
Furthermore, Lp-PLA2–lowering alleles should produce lifelong, rather than shorter-term, Lp-PLA2 inhibition.  95 
In over 260,000 participants of European, South Asian, or East Asian ancestries, we studied five functional 96 
variants in PLA2G7. We compared effects of Lp-PLA2-lowering alleles on soluble Lp-PLA2 activity, 97 
conventional cardiovascular risk factors, and CHD risk with corresponding effects of darapladib, using results 98 
from randomized trials.  99 
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METHODS 100 
Study design 101 
Figure 1 summarises the study approach. Table 1 provides definitions and sources of data used. First, we 102 
identified four loss-of-function mutations and one missense variant in PLA2G7 suggested by previous 103 
experimental and bioinformatics studies, thereby developing an allelic series for Lp-PLA2 activity. Second, we 104 
assessed associations of these variants ─ both singly and in combination ─ with soluble Lp-PLA2 activity, 105 
conventional cardiovascular risk factors, and CHD risk in people of European, South Asian, or East Asian 106 
continental ancestries. Third, we compared associations of Lp-PLA2–lowering alleles with the aforementioned 107 
traits and CHD risk with the effects of darapladib treatment through a systematic review of randomized trials.  108 
Genetic variants 109 
We defined loss-of-function variants as non-synonymous variants with in vitro or in vivo evidence 110 
demonstrating complete lack of Lp-PLA2 activity or sequence changes expected to abolish Lp-PLA2 function 111 
(e.g., nonsense variants or mutations in essential splice sites). We selected variants through a systematic search 112 
for loss-of-function variants using the UniProt database7, the Exome Aggregation Consortium database 113 
(Cambridge, MA, USA; URL: http://exac.broadinstitute.org; [accessed November 2014])8, studies of site-114 
directed mutagenesis9-11 and results from targeted gene sequencing12. Among the full set of variants identified 115 
(eTable1), we selected the following variants that could be detected in the 1000 Genomes13 or the Exome 116 
sequencing14 projects (and, hence, potentially studied at the population level): the splice site mutation 117 
109+2T>C (rs142974898); two non-synonymous variants ─ Arg82His (rs144983904) and Val279Phe 118 
(rs76863441); and the nonsense variant Gln287Ter (rs140020965). These loss-of-function variants are rare in 119 
European and South Asian ancestry populations, whereas carriage of 279Phe is common in East Asian ancestry 120 
populations and abolition of Lp-PLA2 activity is well documented15. Additionally, we studied Val379Ala 121 
(rs1051931), a functional variant common in European ancestry populations, which lowers Lp-PLA2 activity 122 
only modestly9, 16, in contrast with the substantial Lp-PLA2–lowering achieved by the loss-of-function variants 123 
described above.  124 
Samples and data for genetic studies  125 
We aimed to maximise study power and comprehensiveness by using the following complementary approaches 126 
to generate new data on, as well as to collate systematically existing relevant information about, the PLA2G7 127 
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variants mentioned above: (1) we conducted de-novo genotyping for 72,657 CHD patients and 110,218 controls 128 
(the majority of whom also had information available on some cardiovascular risk factors); (2) we accessed non-129 
overlapping summary-level data from the only known global genetics consortium of CHD17, yielding 130 
information on a further 35,735 CHD patients and 73,481 controls; (3) we conducted a systematic review 131 
(supplemented by provision of tabular data from each study investigator) of published East Asian CHD studies 132 
of Val279Phe because these studies were not represented in the global CHD consortium, yielding information 133 
on a further 10,088 CHD cases and 15,199 controls; (4) we accessed summary-level data from the largest 134 
available global genetics consortium on each of several relevant cardiovascular risk factors (eg, Lp-PLA2 135 
activity, conventional lipids, blood pressure), yielding information on 489,045 participants. Each of these 136 
sources of information is summarised below and in Table 1.  137 
Coronary heart disease outcomes For CHD outcomes, we had access to data for a total of 92,995 patients and 138 
162,228 controls. For 182,875 of these participants (72,657 CHD patients, 110,218 controls), we did de-novo 139 
genotyping of the four loss-of-function variants (c.109+2T>C, Arg82His, Val279Phe, Gln287Ter) and 140 
Val379Ala using customized Exome arrays (Illumina, California, USA) by technicians masked to the 141 
phenotypic status of the participants’ samples. For 35,829 CHD cases, 44,948 controls in eight studies, we had 142 
access to individual-participant data. The eight studies were: the Bangladesh Risk of Acute Vascular Events 143 
Study (BRAVE)18, Copenhagen City Heart Study (CCHS)19, Copenhagen Ischemic Heart Disease/Copenhagen 144 
General Population Study (CIHDS/CGPS)19, European Prospective Investigation into Cancer and Nutrition-145 
Cardiovascular Disease Study (EPIC-CVD)20, MONICA Risk, Genetics, Archiving, and Monograph 146 
(MORGAM) study21, 22, Pakistan Risk of Myocardial Infarction Study (PROMIS)23, Pravastatin in elderly 147 
individuals at risk of vascular disease (PROSPER) trial24  and the West of Scotland Coronary Prevention Study 148 
(WOSCOPS)25 (these eight studies are collectively called the “CHD Exome+ consortium”). For 15 additional 149 
studies (collectively called the “MICAD consortium”), we used similar genotyping methods to those described 150 
above but did not genotype c.109+2T>C and had access only to study-level data. We supplemented de-novo 151 
data on Val379Ala with non-overlapping consortium-level results from a further 35,735 CHD patients and 152 
73,481 controls in the transatlantic Coronary Artery Disease Genome-wide Replication and Meta-analysis 153 
(CARDIoGRAM)26 and Coronary Artery Disease Genetics (C4D)27 consortia (Table 1). We obtained tabular 154 
data on Val279Phe from seven East Asian studies involving a total of 10,088 CHD cases and 15,199 controls, 155 
identified through systematic review (eTable 5 and Supplement). About 90% of CHD patients in our genetic 156 
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analysis had myocardial infarction or other major acute coronary events; the remainder had angiographic 157 
evidence alone (eg, >50% coronary stenosis; eTables 2 & 5). 158 
Lp-PLA2 activity For 13,835 participants, we had information on functional variants in PLA2G7 and Lp-PLA2 159 
activity, using data from de-novo genotyping in MORGAM21, 22 and PROSPER24, supplemented by published 160 
data from the CHARGE Consortium (ie, from the Atherosclerosis Risk in Communities [ARIC] Study28, 161 
Cardiovascular Health Study16, Framingham Heart Study16, and Rotterdam study16), and from 12 East Asian 162 
studies identified through the systematic review described above (Table 1, Supplement & eFigure1, eTables 163 
2-3). 164 
Conventional cardiovascular risk factors For 177,343 participants, we had information on functional variants in 165 
PLA2G7 and conventional cardiovascular risk factors and several other traits, including circulating 166 
concentrations of LDL-cholesterol, HDL-cholesterol, triglycerides, glucose, insulin, and C-reactive protein, and 167 
values of systolic and diastolic blood pressure, body-mass index, and estimated glomerular filtration rate. Again, 168 
we supplemented data from our de-novo genotyping, with information from existing global genetics consortia 169 
(Table 1, eTables 2-4).  170 
Randomized trials of darapladib 171 
To compare genetic associations with effects of pharmacological Lp-PLA2 inhibition, we conducted a 172 
systematic review to identify randomized placebo-controlled trials of darapladib that had reported on Lp-PLA2 173 
activity, conventional risk factors, and/or CHD events (Supplement). CHD events in the trials were defined as 174 
fatal CHD, MI or urgent revascularisation, as recorded in STABILITY (Stabilization of Atherosclerotic Plaque 175 
by Initiation of Darapladib Therapy) and in SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-176 
Thrombolysis in Myocardial Infarction 52)5, 6. We pooled results across trials by fixed-effect inverse-variance 177 
weighted meta-analysis (eFigures 2&3; see Supplement for details of the methods used).  178 
Statistical methods 179 
We defined effect alleles as those associated with lower Lp-PLA2 activity and assumed an additive model. For 180 
participant-level data, we assessed associations of Lp-PLA2-lowering alleles with CHD using the genome-wide 181 
efficient mixed model analysis, an approach that models each genetic variant as a fixed-effect, but includes both 182 
fixed-effect and random-effects of genetic inheritance29 to account for population stratification and relatedness 183 
among participants (Supplement). The four rare loss-of-function variants were tested jointly within each study 184 
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by counting the number of loss-of-function alleles carried by each participant. Log odds ratios and standard 185 
errors were meta-analysed across studies using fixed-effect meta-analysis. For studies contributing only study-186 
level data, we performed a similar test by conducting a combined burden test across studies using the R package 187 
seqMeta v1.2 (http://cran.r-project.org/web/packages/seqMeta/).  188 
We calculated associations of Lp-PLA2-lowering alleles with soluble Lp-PLA2 activity and conventional risk 189 
factors using linear regression within each study, and then combined the regression coefficients using fixed-190 
effect meta-analysis. When data were missing, we used information on rs1805018 as a proxy for Val279Phe and 191 
information on rs7756935 or rs3799277 as proxies for Val379Ala (Supplement). To account for population 192 
stratification, we adjusted for the first principal component of ancestry (Supplement). We calculated risk ratios 193 
for CHD with decrements in Lp-PLA2 activity, dividing the log transformed risk ratio and confidence interval 194 
(CI) by the effect on Lp-PLA2 activity of the instrument (ie, the genetic variant)30. We investigated 195 




Of the 261,950 total participants in this analysis, we studied 195,715 individuals of European ancestry, 34,221 199 
individuals of South Asian ancestry, and 32,014 individuals of East Asian ancestry. In people of European or 200 
South Asian ancestry without CHD, the frequency of alleles in PLA2G7 that lower Lp-PLA2 activity was 201 
0.005% at c.109+2T>C, 0.04% at Arg82His, 0.04% at Val279Phe, and 0.025% at Gln287Ter (i.e., in aggregate, 202 
0.2% of the European or South Asian participants in the current study carried one of these loss-of-function 203 
alleles, although no one carried more than one of these variants), and about 80% at Val379Ala. In people of East 204 
Asian ancestry without CHD, the frequency of Val279Phe was about 15% and about 2% of the individuals were 205 
homozygous carriers of the 279Phe allele. 206 
Soluble Lp-PLA2 activity 207 
Compared with non-carriers, homozygote carriers of the 279Phe allele had 94% lower Lp-PLA2 activity (p<10-208 
300). For each 279Phe allele inherited, Lp-PLA2 activity decreased by 45% (1.59 SD, 95% CI: 1.61-1.57; p<10-209 
300). In Europeans who inherited any one of the four rare Lp-PLA2 loss-of-function alleles, Lp-PLA2 activity 210 
decreased by 64% (2.25 SD, 2.68-1.83; p=1.6×10-25). For each 379Ala allele inherited, Lp-PLA2 activity 211 
decreased by 2.7% (0.096 SD, 0.122-0.069; p=1.9×10-12). By comparison, 160mg once-daily darapladib reduced 212 
Lp-PLA2 activity by 65% (2.26 SD, 2.31-2.21; p<10-300). Study-level estimates are provided in eFigure 2. 213 
Cardiovascular risk factors 214 
None of the Lp-PLA2–related variants we studied was significantly associated with values of LDL-cholesterol, 215 
HDL-cholesterol, triglycerides, systolic or diastolic blood pressure, body-mass index, estimated glomerular 216 
filtration rate, glucose, insulin, and C-reactive protein (Figure 2). By comparison, in previous randomized 217 
placebo-controlled trials, darapladib did not significantly affect concentrations of LDL-cholesterol or log 218 
triglycerides, but could have slightly increased systolic blood pressure and HDL-cholesterol values and slightly 219 
decreased C-reactive protein concentration (Figure 2). 220 
221 
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Clinical CHD outcomes 222 
Compared to non-carriers, the odds ratio for CHD was 0.99 (0.95-1.03) in 279Phe heterozygotes, and 0.93 223 
(0.82–1.05) in 279Phe homozygotes (i.e. nearly complete loss of Lp-PLA2 function: Figure 3). For each loss-of-224 
function (279Phe) allele inherited, the odds ratio for CHD was 0.97 (0.91-1.02; I2=30%; PHeterogeneity=0.2). In 225 
Europeans and South Asians who inherited one of the four rare Lp-PLA2-loss-of-function alleles, the odds ratio 226 
for CHD was 0.92 (0.74-1.16; I2=0%; PHeterogeneity=0.8; Figure 3). For each 379Ala allele inherited, the odds 227 
ratio for CHD was 1.00 (0.98-1.02; I2=0.0%; PHeterogeneity=0.5; Figure 3). Study-level results are provided in 228 
eFigure 3. In sensitivity analyses, odds ratios with each loss-of-function variant were similar to the odds ratio 229 
that combined information across the four loss-of-function variants we studied. There was no evidence of 230 
heterogeneity in odds ratios between European and South Asian ancestry populations (eFigure 4).  231 
Genetic risk ratios for CHD per 65% lower Lp-PLA2 activity (i.e. the reduction achievable with darapladib 232 
treatment) were: 0.95 (0.88-1.03) with Val279Phe in East Asians; and 0.92 (0.74-1.16) with carriage of any one 233 
of the four rare variants studied in Europeans and South Asians; and 1.01 (0.68-1.51) with Val379Ala (Table 2). 234 
By comparison, the risk ratio for CHD with darapladib treatment (i.e. also per 65% lower Lp-PLA2 activity) was 235 




In 2008, GlaxoSmithKline launched a ~$1 billion program of phase 3 trials of darapladib, a compound which 239 
did not reduce cardiovascular event rates in two secondary prevention trials. We tested whether Lp-PLA2 240 
enzyme activity is causally relevant to CHD by studying five functional alleles that produce widely differing 241 
degrees of reduction in Lp-PLA2 activity. We found that none was related to CHD risk. Hence, our large-scale 242 
human genetic data, which are concordant with results from phase 3 trials, suggest that Lp-PLA2 enzyme 243 
activity is not causally relevant to CHD. The implication is that darapladib did not reduce CHD risk in recent 244 
trials principally because Lp-PLA2 is not a valid therapeutic target.  245 
Three features of our study merit comment. First, we studied almost 20 times more CHD patients than the 246 
previous largest study of loss-of-function PLA2G7 alleles, thereby providing the first robust genetic evaluation 247 
of effect sizes of Lp-PLA2 inhibition relevant to phase 3 trials such as relative risk reductions for CHD of 20%. 248 
For example, for the Val279Phe variant we had >99% power to detect a 20% risk reduction in CHD for a 65% 249 
genetic reduction in Lp-PLA2 activity (ie, an effect on Lp-PLA2 activity similar to that achieved by darapladib). 250 
Second, our study has provided the first investigation in CHD of a series of functional alleles that each reduce 251 
Lp-PLA2 function via different molecular mechanisms. Specifically, we studied five different Lp-PLA2-252 
lowering alleles: three of the alleles were coding variants that produced different amino acid substitutions; two 253 
of the alleles produced protein truncations (one due to a nonsense mutation; the other due to a splice-site 254 
mutation). Because we observed null and broadly concordant findings for CHD risk across these alleles that 255 
each changed the enzyme in a different way, we can more confidently conclude there is no material cause-and-256 
effect relationship. By contrast, when the initial phase 3 trial of darapladib was launched in 2008, only two of 257 
the five alleles we studied had yet been identified: data on Val379Ala, a weak effect missense variant, were 258 
inconclusive because CHD studies were under-powered31; data on Val279Phe, a loss-of-function variant, and 259 
CHD risk were sparse and restricted to East Asian populations.  260 
A third feature was our study’s analysis of substantial data from three different major ethnic groups: Europeans, 261 
South Asians, and East Asians. This ethnic diversity enhanced the generalisability of our results.  262 
Our study had potential limitations. We used the “major coronary events” endpoint from phase 3 darapladib 263 
trials for comparison of pharmacological inhibition of Lp-PLA2 with genetic inhibition, whereas definitions of 264 
CHD used in human genetic studies were not strictly uniform (eg, some studies included patients with only 265 
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angiographic evidence of CHD). However, about 90% of CHD cases included in our genetic analyses had 266 
myocardial infarction or other major acute coronary events.  267 
It could be that cardioprotective benefits of Lp-PLA2 inhibition were obscured by pleiotropic effects of PLA2G7 268 
variants; for example, 279Phe is known to produce a misfolded version of Lp-PLA2 not secreted by cells, 269 
prompting suggestions that its carriage could produce “off-target” effects such as increased cell death32, 33. 270 
However, because we found null associations between four other functional alleles in PLA2G7 and CHD, each 271 
of which operates via a different molecular mechanism, it argues against this explanation.  272 
Lifelong genetic reductions in Lp-PLA2 could result in compensatory responses that increase CHD risk. 273 
However, this explanation seems unlikely because it would require any such compensation to apply similarly 274 
across alleles that produce widely differing degrees of reduction in Lp-PLA2 activity. Furthermore, any such 275 
compensation could not operate through known cardiovascular mechanisms because we observed no 276 
associations between Lp-PLA2-lowering alleles and several established and emerging cardiovascular risk 277 
factors.  278 
Soluble enzyme activity could be an imperfect indicator of the relevance of Lp-PLA2 to atherosclerotic plaques. 279 
However, for homozygote carriers of 279Phe, Lp-PLA2 activity should be almost abolished across all tissues. 280 
Finally, we studied life-long genetic reductions in Lp-PLA2 activity in relation to first-onset CHD outcomes 281 
rather than recurrent CHD, whereas darapladib trials studied recurrent coronary events in patients with stable or 282 
acute coronary disease.  283 
Our findings suggest that, in retrospect, the lack of efficacy of darapladib in phase 3 trials could, in principle, 284 
have been anticipated. However, it is important to acknowledge that the methods and data used in the current 285 
analysis were not available at the time the darapladib program was launched. Nevertheless, the current data 286 
underscore the growing importance of human genetic approaches to enhance the efficiency of development of 287 
medicines by validating (or invalidating) novel drug targets34-37. Our results also illustrate how human genetic 288 
evidence can assist interpretation of observational epidemiological data. We found that functional alleles in 289 
PLA2G7 do not alter levels of pro-atherogenic lipds (eg, LDL-C). This result suggests that such pro-atherogenic 290 
lipids do not mediate associations between Lp-PLA2 activity and CHD, supporting the need to adjust 291 
epidemiological associations of Lp-PLA2 activity with CHD risk for pro-atherogenic lipds (an approach which 292 
yields results consistent with non-causality)2.  293 
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In summary, none of a series of Lp-PLA2–lowering alleles was related to CHD risk, suggesting that Lp-PLA2 is 294 
not a valid therapeutic target.  295 
296 
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Table 1: Definitions and source of contributing data for the main study outcome 747 
 748 
^ In genetic analysis, CHD was defined as myocardial infarction and other major coronary events (~90% of cases) or angiographic stenosis only (~10% of cases) see eTables 2 & 3 for details. In the darapladib analysis CHD was defined as fatal coronary disease, non-fatal MI or urgent 749 
revascularization for myocardial ischaemia. 750 
$ See eTables 2 & 3 for details on risk factor measurements 751 
rs142974898 (c.109+2T>C), rs144983904 (Arg82His), rs76863441 (Val279Phe), rs140020965 (Gln287Ter); see also Figure 1B for further variant details; BMI = Body-mass index, eGFR = estimated glomerular filtration rate, NA= Data not available. Further detail on the individual studies 752 
is provided in eTables 2-3.  753 
CARDIoGRAM=Coronary ARtery DIsease Genome wide Replication and Meta-analysi; CHARGE=Cohorts for Heart and Aging Research in Genomic Epidemiology; CKDGen=Chronic Kidney Disease GENetics consortium; GIANT=Genetic Investigation of ANthropometric Traits 754 







common in East 
Asians‡ 
Four loss-of-function variants*, rare in 
Europeans & South Asians† 
Val379Ala, modest impact variant Darapladib 
Data sources Systematic review: 
Study-level data from 
up to 12 East Asian 
studies 
De-novo genotyping and participant-level data: up to 8 European or or South Asian ancestry studies from the CHD Exome+ Consortium18-25; 
De-novo genotyping  and study-level data: up to 15 European ancestry studies from the MICAD Exome consortium37 and 3 European ancestry studies from the 
CHARGE Consortium16, 28; 
Plus publicly available consortium data   
Systematic review:  
Study-level data from up to 5 
randomized clinical trials5, 6, 
38-40 from a systematic review 
Endpoint Number of studies and unique individuals contributing to analyses; n total or cases / controls 
Coronary 
heart disease^ 
7 East Asian studies 8 European or South 
Asian ancestry 
studies from the  
CHD Exome+ 
Consortium18-25 
15 European ancestry 
studies from the 
MICAD Exome  
consortium37 
8 European or South 
Asian ancestry studies 
from the CHD Exome+  
Consortium18-25 
8 European ancestry 
studies from the 
MICAD Exome  
consortium37 
14 European ancestry 
studies from the 
CARDIoGRAM 
consortium26 
4 European or South Asian 
ancestry studies from the C4D 
consortium27 
2 phase III randomized 



















12 East Asian studies 1 European ancestry 
study from the CHD 
Exome+ 
Consortium24 
1 European ancestry 
study from the 
CHARGE 
Consortium28 
2 European ancestry studies from the CHD 
Exome+ Consortium21, 22, 24 
3 European ancestry studies from the CHARGE 
consortium16  
3 phase II randomized 
clinical trials38-40  
8468 1240 8564 2173 11,662 854 
Conventional 
risk factors$ 
12 East Asian studies 8 European or South Asian ancestry studies 
from the CHD Exome+ Consortium18-25 
8 European or South Asian ancestry studies from 
the CHD Exome+ Consortium18-25 
Publicly available consortium data 5 randomized clinical  trials5, 
6, 38-40 
BMI 17,898 76,584 51,201 126,142  from 46 studies from the GIANT Consortium41 NA 
Blood pressure 6705 72,450 71,256 69,245 from 29 studies from the ICBP Consortium42 323 
Lipids 17,643 76,826 55,431 94,311 from 46 studies from the GLGC Consortium43 803 
C-reactive 
protein 
2914 40,484 41,442 66,185 from 15 studies from the CHARGE Consortium44 848 
Glycaemic 
traits 
2914 9420 9408 46,186 from 21 studies from the MAGIC Consortium45 NA 
eGFR 4017 32,929 32,190 74,354 from 26 studies from the CKDGen Consortium46 NA 
29 
Table 2: Comparison on a common scale of human genetic and randomized trial evidence for Lp-PLA2 lowering and CHD 758 
 CHD patients Controls Risk ratio for CHD per 65% lower Lp-PLA2 
activity (95% CI) 
Genetically lowered Lp-PLA2    
Val279Phe (East Asian LoF variant) 10,088 15,199 0.95 (0.88 - 1.03) 
Four LoF variants* 71,362 109,078 0.92 (0.74 – 1.16) 
Val379Ala 82,907 147,029 1.01 (0.68 – 1.51) 
    
Pharmacologically lowered Lp-PLA2    
Darapladib 3364 25,490 0.95 (0.89 – 1.02) 
* Carriage of any of the four loss-of-function variants c.109+2T>C, Arg82His; Val279Phe; Gln287Ter; LoF = Loss-of-function 759 
 760 
30 
Figure 1: Summary of study design 761 
 762 
A) Flow chart of study design B) Exonic structure of the PLA2G7 gene and location of variants used in this study.; ExAc = Exome Aggregation consortium, Lp-PLA2 = Lipoprotein-associated phospholipase A2, RCT = 763 
Randomized controlled trial, UniProt/Swissprot = Manually annotated and reviewed section of the Universal Protein resource database.764 
Genetic inhibition 
of Lp-PLA2
• Four loss-of-function variants
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Loss-of-function variants Modest impact variant
31 
Figure 2  765 
 766 
To enable comparison of the magnitude of associations across several different markers, analyses were undertaken with standardized units of measurement for each marker. Associations are presented as per allele 767 
change in the biomarker expressed as standard deviations. * Carriage of any of the four loss-of-function variants c.109+2T>C, Arg82His; Val279Phe; Gln287Ter; BMI = Body-mass index, DBP = Diastolic blood 768 
pressure, eGFR = estimated glomerular filtration rate, HDL-c = High-density lipoprotein cholesterol, LDL = low-density lipoprotein cholesterol, LoF = Loss-of-function, Lp-PLA2 = Lipoprotein associated 769 
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32 
Figure 3 771 
 772 
Spectrum of functional alleles in PLA2G7 and effects on Lp-PLA2 activity (red estimates) and coronary heart disease risk (black estimates); * Carriage of any of the four loss-of-function variants c.109+2T>C, 773 
Arg82His; Val279Phe; Gln287Ter; † One study did not provide tabular data to enable calculation of CHD odds ratios in heterozygotes or homozygotes. Hence, numbers are less than those presented for the per allele 774 














































































Homozygotes (complete LoF) vs. 
common homozygotes 
Cases 82,907 8789† 71,362 3364 6983†
Controls 147,029 13,190† 109,078 25,490 10,206†
Participants 13,835 8264 9804 854 5997
Analysis of coronary 
heart disease 
outcomes
Analysis of soluble 
Lp-PLA2 activity
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